Metabolism inhibitors, such as HIF-1α inhibitor[30,31], Glut-1 inhibitor[32,33], CAIX inhibitor[34], and monocarboxylate transporter (MCT)4 inhibitor[35], are reported in preclinical studies to suppress tumor growth in several tumor types. This evidence concerns the gene SLC2A1 and neoplasm.